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Background: Voriconazole is metabolized by cytochrome P450 (CYP) 2C19 and CYP 3A4. Drug-drug interactions
and genetic polymorphisms modulate their activities.
Case presentation: A 35-year old African female patient with resistant HIV and a cerebral mass of unknown origin was
treated with voriconazole for a suspicion of disseminated Aspergillosis infection. Voriconazole trough concentrations (C0)
were within target range while the patient was under esomeprazole, a CYP2C19 inhibitor. Phenotyping showed
decreased CYP2C19 activity, whereas genotyping showed a variant allele associated with increased enzyme activity.
The patient was switched to ranitidine because of the introduction of atazanavir. CYP3A4 inhibition by atazanavir
combined with uninhibited CYP2C19 activity resulted in subtherapeutic voriconazole C0. The reintroduction of
esomeprazole allowed restoring voriconazole C0 back to target range.
Conclusion: The integration of drug-drug interactions and pharmacogenetics data is crucial to interpret drug
concentrations correctly, thus preventing suboptimal exposure to voriconazole.
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Voriconazole is used as an antifungal agent in the treat-
ment of suspected or known Aspergillosis infection. [1]
Voriconazole is mainly metabolized by cytochrome P450
(CYP) 2C19 and 3A4, [2] and its clearance is modulated
by drug – drug interactions (DDI) [3,4] and genetic
polymorphisms [5-7]. We report a case of multiple DDI
in a patient with an increased CYP2C19 activity that led
to variations in voriconazole trough concentrations (C0).
Voriconazole C0 reached and stayed within the targeted
range with the use of inhibitors of CYP2C19 and
CYP3A4.
A 35-year old Cameroonian female was diagnosed
with AIDS (CDC stage C3) in May 2012. A duodenal
histoplasmosis and cryptococcosis infection were treated
from June 2012 with a 3-week course of amphotericin* Correspondence: Yassine.Bouatou@hcuge.ch
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unless otherwise stated.B – flucytosine followed by oral voriconazole 100 mg
bid. A combined antiretroviral regimen (cART) was
initiated (emtricitabine, tenofovir and raltegravir). As
she developed a single large intracranial mass, voricona-
zole was given intravenously and doses were increased up
to 4 mg/kg/12 h. A cerebral biopsy showed aspecific in-
flammatory infiltrates with-T lymphocytes, negative gram
stain and broad range PCR. As the lesion was associated
with a voluminous edema, she was started on IV dexa-
methasone (3 mg tid) progressively tapered over 1 month.
The proton pump inhibitor (PPI) esomeprazole 40 mg bid
was started because of severe epigastralgia associated with
duodenal histoplasmosis.
Voriconazole first C0 was subtherapeutic (<1.0 μg/mL;
range 1.0 - 5.0 μg/mL [3]) (Figure 1). The patient was
genotyped for CYP2C19. It came heterozygous for the
variant allele CYP2C19*17 (c.-860C > T; rs12248560)
that is associated with an increased enzyme activity.
Phenotyping with 2 mg omeprazole, while on CYP2C19
inhibitor esomeprazole, showed decreased CYP2C19l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Time course of patient treatment and therapeutic drug monitoring results. Time course of (A) voriconazole i. v. dosage administration,
(B) comedication with esomeprazole or ranitidine and (C) associated antiretroviral therapy. Voriconazole plasma trough concentrations. qd: once a day;
b.i.d.: Twice a day.
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that time voriconazole C0 was within the therapeutic
range.
Due to several HIV resistance mutations and hepatitis B
status, cART was modified with the addition of abacavir
in order to increase cerebral penetration of unboosted ata-
zanavir together with maintenance of emtricitabine/teno-
fovir. Atazanavir absorption depends on gastric acidity.
The patient was switched from esomeprazole to the
histamine-2 receptor antagonist ranitidine, which is less
potent in suppressing intragastric pH.
Several voriconazole C0 were then measured below the
therapeutic range despite substantial increased dosing
(Figure 1). Darunavir - ritonavir regimen was introduced
because of therapeutic failure and atazanavir was stopped.
The patient presented with new onset epigastralgia and
anemia. Ranitidine was replaced by esomeprazole 40 mg
IV bid. Three days later, voriconazole C0 increased 14-fold
and the voriconazole dose was reduced by 50% (2.5 mg/kg
bid). There were no other medication changes. Subse-
quent voriconazole C0 stayed within the therapeutic range.However the patient’s condition deteriorated as she devel-
oped progressive multifocal leukoencephalopathy. She
eventually died four months later.
CYP2C19 activity is modulated both by genetic poly-
morphisms and drug – drug interactions. Our patient was
heterozygous for CYP2C19*17. Its frequency is approxi-
mately 21% in Caucasians, 16% in African-Americans, and
3% in Asians [8]. This allele is associated with increased
enzymatic activity and may decrease voriconazole expos-
ure compared to homozygous wild type extensive metabo-
lizers [7,9]. CYP2C19 phenotype was performed [10]
under high doses of esomeprazole, a CYP2C19 inhibitor.
It explains the reduced enzymatic activity despite the
patient’s genotype. Voriconazole C0 was within the
therapeutic range when associated with the proton pump
inhibitor [11]. It was subtherapeutic when the patient re-
ceived ranitidine, which has no influence on CYP activity
and voriconazole concentrations [12]. Atazanavir is a
CYP3A4 inhibitor [13]. Hence voriconazole clearance
depended only on uninhibited CYP2C19. When ataza-
navir was stopped, boosted darunavir was introduced.
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increased voriconazole concentration. [2] However re-
peated administration of ritonavir induces CYP2C19
metabolic activity and potentially causes a reduction in
voriconazole exposure [14]. The magnitude of the effect
depends on the dose administered. The net effect of low
dose ritonavir and inhibition of CYP2C19 by high-dose
esomeprazole is likely to be a decrease in enzyme meta-
bolic activity.
After esomeprazole was reintroduced, the patient was
taking both a CYP2C19 and a CYP 3A4 inhibitor, and vori-
conazole plasma levels reached therapeutic concentrations.
Double blockade of voriconazole metabolic pathways
(CYP2C19 and CYP3A4) led to concentrations within
the therapeutic range in a patient genetically susceptible
to subtherapeutic voriconazole concentrations. This case
illustrates how the integration of drug-drug interactions
and pharmacogenetics can help interpret drug concentra-
tions during therapeutic drug monitoring, and thus
minimize the risk of suboptimal exposure to voriconazole.
The “boosting strategy” is mainly used in the fields of HIV
therapeutics with antiretroviral drugs such as ritonavir
or cobicistat and its efficacy to overcome specific CYP
genotypes has not been evaluated so far.Consent
Written informed consent was obtained from the patient
for publication of this Case report and any accompanying
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